// App-Quantinova.ai

7523 : Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.

Researchers

Presenter

  • Paul M. Barr

Principal Investigators

  • Tadeusz Robak

  • Alessandra Tedeschi

  • Osnat Bairey

  • Jan Andreas Burger

  • Peter Hillmen

  • Steve E. Coutre

  • Stephen Devereux

  • Sebastian Grosicki

  • Helen McCarthy

  • Jianyong Li

  • David Simpson

  • Fritz C. Offner

  • Carol Moreno

  • Sandra Dai

  • Anita Szoke

  • James P. Dean

  • Thomas J. Kipps

  • Paolo Ghia

Medical Centers

  • Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada

  • Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland

  • Grande Ospedale Metropolitano Niguarda, Milan, Italy

  • Rabin Medical Center, Petach Tikvah, Israel

  • The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Houston, TX

  • The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, United Kingdom

  • Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA

  • College Hospital, NHS Foundation Trust Denmark Hill, London, United Kingdom

  • School of Public Health, Silesian Medical University,Katowice,Poland

  • Royal Bournemouth Hospital and Poole General Hospital, Bournemouth, United Kingdom

  • Jiangsu Cancer Hospital, Nanjing, China

  • North Shore Hosp, Auckland, New Zealand

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • Hospital de la Santa Creu i Sant Pau, Hematology Department, Autonomous University of Barcelona, Barcelona, Spain

  • Pharmcyclics LLC, an AbbVie Company, Sunnyvale, CA

  • UC San Diego Moores Cancer Center, San Diego, CA

  • Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

Locations

  • Canada

  • Poland

  • Italy

  • Israel

  • United Kingdom

  • China

  • New Zealand

  • Belgium

  • Spain

Companies

  • Pharmacyclics LLC

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • chlorambucil

  • Ibrutinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01722487

  • NCT01724346

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved